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Abstract
Background The incidence of skin cancers has been increasing steadily over the last decades. Although there have
been significant breakthroughs in the management of skin cancers with the introduction of novel diagnostic tools and
innovative therapies, skin cancer mortality, morbidity and costs heavily burden the society.
Objective Members of the European Association of Dermato-Oncology, European Academy of Dermatology and
Venereology, International Dermoscopy Society, European Dermatology Forum, European Board of Dermatovenereol-
ogy of the European Union of Medical Specialists and EORTC Cutaneous Lymphoma Task Force have joined this effort
to emphasize the fundamental role that the specialist in Dermatology–Venereology has in the diagnosis and manage-
ment of different types of skin cancer. We review the role of dermatologists in the prevention, diagnosis, treatment and
follow-up of patients with melanoma, non-melanoma skin cancers and cutaneous lymphomas, and discuss approaches
to optimize their involvement in effectively addressing the current needs and priorities of dermato-oncology.
Discussion Dermatologists play a crucial role in virtually all aspects of skin cancer management including the imple-
mentation of primary and secondary prevention, the formation of standardized pathways of care for patients, the estab-
lishment of specialized skin cancer treatment centres, the coordination of an efficient multidisciplinary team and the
setting up of specific follow-up plans for patients.
Conclusion Skin cancers represent an important health issue for modern societies. The role of dermatologists is cen-
tral to improving patient care and outcomes. In view of the emerging diagnostic methods and treatments for early and
advanced skin cancer, and considering the increasingly diverse skills, knowledge and expertise needed for managing
this heterogeneous group of diseases, dermato-oncology should be considered as a specific subspecialty of Dermatol-
ogy–Venereology.
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Introduction
Dermato-oncology is a rapidly evolving branch of Dermatology–
Venereology focusing on the prevention and management of
both common and rare forms of cutaneous malignant tumours,
ranging from melanoma and epithelial skin cancers to tumours
of neuroendocrine and lymphoid origin. The strong increase in
the incidence of melanoma and other skin cancers, enhanced by
increased life expectancy and population ageing along with the
introduction of in vivo diagnostic tools (e.g. dermatoscopy) and
new treatments for advanced melanoma and non-melanoma
skin cancers (NMSCs) have resulted in unprecedented changes
in the organization of patient care in the clinical setting. The
present paper highlights current priorities in the field of der-
mato-oncology (as illustrated in Fig. 1) and reviews the funda-
mental role of dermatologists in the prevention, diagnosis and
treatment of skin cancer.
Mastering the skin cancer epidemic
The incidence of skin cancers is increasing across all Europe,
although with different speed and patterns across East-West
and North-South regions (Fig. 2).1,2 With few limited excep-
tions,3 this trend is expected to continue strongly. In Central
Europe, the incidence of melanoma and NMSCs was roughly
1 and 5 cases per 100 000 in 1950, respectively.4,5 In Ger-
many, 25 and 250 cases per 100 000 inhabitants have been
diagnosed with melanoma and NMSC in 2010, respectively,
and about 45 and 400 cases of melanoma and NMSCs per
100 000 inhabitants, respectively, are expected in 2030.6,7 It
is estimated that, over a period of 80 years, the incidence of
melanoma will increase 45-fold and that of NMSC 80-fold.
There are similar increases in the incidence of skin cancer in
Western white populations worldwide.3 So far, in Europe
there is no clear trend of reversal, while in Australia the first
signs of a levelling-off of the incidence of melanoma have
been observed, eventually driven by significantly higher num-
bers of patients with skin cancers.3
In order to better understand the skin cancer epidemic, it is
important to recognize its two driving forces: the massive
increase of human exposure to ultraviolet radiation (UVR) in
the last half-century, and the ageing of the population – espe-
cially the skin cancer-prone Caucasian population (Table 1). It
has been well established epidemiologically that melanoma, as
well as most NMSCs, is mainly caused by UVR.8,9 In Australia
and the United States, about 95% of cutaneous melanomas are
estimated to be caused by UVR.10,11 Several other factors play a
role in the increasing trends of skin cancer, such as the increase
in early diagnosis and reporting of cases through increased
awareness, improved diagnosis, as well as expanding cancer reg-
istries. In contrast with the dramatic increase in incidence, the
mortality of skin cancers is plateauing,1,12 a trend which is usu-
ally attributed to improved management, but also raises the
question of overdiagnosis as a result of increased diagnostic
scrutiny. There is also a staggering increase in the medical costs
of diagnosis and management, with the use of more complex
diagnostic testing and expensive innovative drugs for advanced
disease, now also employed in earlier stages of the disease as
adjuvant treatment. In a recent study from Australia, it was
reported that the mean annual cost per patient for melanoma
stage 0/I/II was US$1175, rising to US$80 440 for stage III/IV.13
In addition, the treatment of basal cell carcinoma and squamous
cell carcinoma in 2011 in the United States was associated with
costs of up to US$4.8 billion.14 Thus, the increased incidence
causes a ‘snowball’ of growing mortality and morbidity burden,
as well as of human, societal and material costs, which are all
facets of the complex ‘skin cancer epidemic’.
In order to address this epidemic, action needs to be taken at
multiple levels: (a) primary prevention – actions towards reduc-
tion of UVR exposure in the general and high-risk populations,
(b) secondary prevention, mainly focusing on the early detection
of thick, aggressive tumours and tumours that develop in indi-
viduals at high risk for unfavourable outcomes, and (c) expan-
sion and improvement of skin cancer registration in order to
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generate data that will allow specialists to monitor the epidemic,
measure the efficacy of preventive strategies and plan appropri-
ate interventions.
For improvement of cancer reporting, pressure by the civil
society, including not only researchers and physicians, but also
the patients and public, should be put on policymakers and
stakeholders to ‘listen to science’15 and allocate the appropriate
resources and priorities to the building and maintenance of
high-quality, independent-functioning and open-research, pop-
ulation-based cancer registries across all European regions.
Without them, any efforts to master the cancer epidemic would
be like a journey without a compass.
Reorientation of primary and secondary
prevention
Despite numerous preventive initiatives and increased public
awareness, the burden of skin cancer on public health remains
significantly high. Therefore, there is an urgent need to critically
review the existing skin cancer prevention strategies, in order to
determine where targeted efforts may improve patient out-
comes.16–18
Primary skin cancer prevention is mainly focused on limiting
the amount of solar UV exposure and avoiding artificial UVR
exposure (i.e. sunbeds). Although skin cancer can affect any
individual at any age, it usually develops in individuals over 50.
The modifiable risk factors for skin cancer relate to UVR expo-
sure behaviours, such as a history of prolonged sun exposure (ei-
ther at work or for leisure), a history of sunburns, especially in
younger ages, and regular use of sunbeds. These add to genetic
and phenotypical factors like having more than 50 moles on the
whole body, having fair skin or propensity to sunburn, a family
history of melanoma/skin cancer or immunosuppression (e.g.
organ transplant recipients [OTRs]). Avoiding excessive UV
exposure, especially in childhood and adolescence, is thus a
cornerstone in any public health prevention initiative.19–22
Sunscreens have been an important component to this strat-
egy and, as shown in prospective controlled studies, their regular
use has a protective role against melanoma and certain types of
skin cancer (e.g. NMSCs).23 However, their use as an effective
protective agent against UVR remains more of a feasibility issue
in terms of the frequency and amount of sunscreen needed for
optimal protection. Due to unclear messages, the general popu-
lation seems to erroneously believe that the exclusive use of sun-
screens during sunbathing eliminates or significantly reduces the
effect of sunbathing on melanoma and NMSC risk. On the other
hand, it is important to consider that UVR also has several
Primary 
Prevention
Educate the public*
Talk with Legislators to change laws in regards to UV radiation exposure (tanning beds, 
occupational exposure, etc.)
Educate the public*
Self-examination & to seek physician skin examination
Train non-HCPs (e.g. hairdressers) in identifying SC 
Establish guidelines & identify ideal population for screening
Establish continuous training/updates for HCPs
Create standardized patient management algorithms
Interact with payers to improve patient access to more innovative treatments
Encourage formation of multidisciplinary tumor boards for more complex cases
Facilitate access of patients to RCTs
Secondary 
Prevention
Tertiary Prevention
&
Skin Cancer 
Patient Management
Figure 1 Actions/priorities in dermato-oncology. *Collaborate with authorities and scientific communities to organize campaigns and
other actions. HCPs: healthcare providers; RCTs: randomized controlled trials; SC: skin cancer; UV: ultraviolet.
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positive effects for our overall health by enhancing our mood,
relieving stress, improving sleep, treating seasonal depression
and maintaining vitamin D production. Although strict sun
avoidance is not required, skin cancer primary prevention mea-
sures that include sun protection should be implemented. Our
main message should emphasize that being sun-safe is compati-
ble with all hobbies, sports or activities (except tanning for tan-
ning’s sake), and that protection from excessive sun exposure
should be done through a common-sense combination of meth-
ods, including shade, clothing, sunglasses and broad-spectrum
high SPF sunscreens for uncovered body parts 24,25. Along this
line, sunscreens need to be positioned as auxiliary methods of
protecting uncovered, limited body surfaces, for a limited time,
not replacing shade and clothing and not extending the time in
the sun. The use of sunscreen as part of a daily routine to reduce
incidental sun exposure will also contribute to reducing overall
UVR-induced skin damage (Table 2).
Secondary prevention encompasses the various strategies of
early detection of skin tumours, including skin cancer screening
(SCS) programmes. These strategies are expected to reduce the
epidemiologic burden and the cost of skin cancer management,
on the premise that skin cancer can be more easily and effec-
tively treated at an early phase of development. In 2008, a
nationwide SCS programme for the general population was
introduced in Germany. So far, it is credited with contributing
to earlier detection and treatment of skin cancer,26 but it has not
clearly proven to reduce melanoma mortality. With insufficient
scientific evidence supporting its benefits, the applicability for
general population SCS is limited. Therefore, shifting and better
targeting screening efforts towards high-risk groups, including
men over 60 years of age, immunosuppressed patients like OTRs
or patients with HIV/AIDS, and socioeconomically less-privi-
leged individual,27–29 could prove to be a more effective
approach in improving the outcomes of secondary prevention
measures.12,30 Additional high-risk groups, such as patients on
immune-mediated treatments for chronic inflammatory condi-
tions and cancer survivors, should also be a focus of targeted
prevention.
Dermatologists are the best trained and equipped specialists
to provide early detection, but their success depends on insuring
the timely access of patients to their services. There are several
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Figure 2 Data regarding cutaneous melanoma in Germany. The
Danish Cancer Registry records the incidence of melanoma since
1943 and mortality since 1953, and has the longest continuous
documentation in Europe. The crude incidence and mortality rates
are presented here, which also reflect demographic changes with
increased life expectancy in contrast to age-standardized rates. (a)
Crude incidence rates for males and females 1943 - 2017 (b) Crude
mortality rates for males and females 1953 – 2017. (Graph devel-
oped from the freely accessible data from the Danish Cancer Reg-
istry: https://www-dep.iarc.fr/NORDCAN/english/frame.asp).
Table 1 Causes of increased UVR exposure of populations
• Massive increase in intentional exposure after the Second World War,
motivated by the desire to get a tan with sunbathing and tanning salons, in
contrast to sun avoiding behaviour before this period (a tan has become
desirable, heavily promoted as the new beauty and attractiveness ideal).
• Unintentional exposure and incidental sunburns resulting from the radical
change of lifestyle (holidays, global travel, outdoor sports) and fashion
style.
• Occupational exposure (i.e. unprotected exposure of outdoor workers).
Table 2 Summary of sun protection measures
• Avoid intentional UV exposure with the purpose of getting a suntan
(both natural sunbathing and sunbeds).
• Avoid or limit sudden, unintentional, intense direct exposure to the
sun while working or pursuing leisure activities.
• Encourage UV protection through clothing. Clothing provides the best
protection from intense sunlight: a wide-brimmed hat, UV ray-filtering sun-
glasses (since UV rays are also harmful to the eyes) and T-shirts (prefer-
ably darker-coloured clothing of tightly woven material, and for intense
insolation with certified UV protection). Clothing and swimming suits for
children with built-in sun protection [up to sun protection factor (SPF) 50]
are available.
• Provide shade – encourage institutions to provide shading structures as
far as possible in schools, play areas, sports facilities or outdoor working
sites.
• Employ supplementary use of sunscreens in areas of the body that
cannot be protected by clothing. Sunscreen should have the highest
SPF and provide equal protection from UVA and UVB rays. Sunscreen
products are effective immediately after they are applied to the skin. How-
ever, the dose normally used is much lower than necessary to achieve the
stated SPF. It is therefore recommended to apply them once in the morn-
ing and a second time immediately before sun exposure. They should be
reapplied after bathing or heavy sweating.
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studies showing that detection of earlier stage melanoma and
improved patient survival is associated with care by a dermatolo-
gist rather than a non-dermatologist.31 In addition, a greater
density of dermatologists in a given geographical area has been
associated with lower melanoma mortality compared to areas
lacking dermatologists.31 These results suggest that increasing
access to dermatologists may represent a useful approach to
improving melanoma-related health outcomes.32 Still, dermatol-
ogists cannot realistically see the whole population at random
twice a year. This fact points to the major role of self-surveillance
and self-examination together with raising public awareness.
New digital technologies, including smartphone apps, can be
used for health education and to support skin self-examination
and lesion monitoring, complementing access to the expert der-
matologist. In a personalized medicine era, individual patients
are willing to participate in more aspects of their health care.
Although primary and secondary prevention are beneficial and
cost-effective,14,33–35 it is important to optimize ways to improve
the dissemination and effectiveness of all types of prevention
measures.
Quality assurance in the diagnosis and treatment
of skin cancer – Guideline development
Quality assurance relies on the implementation of highly stan-
dardized procedures in diagnosing, documenting and treating
cutaneous tumours. ‘Standard operating procedures’ (SOPs)
must be designed based on high-quality evidence-based medi-
cine data and ideally should be implemented in all cancer cen-
tres. Quality assurance generally consists of three steps: (a)
assessment of the quality of current procedures and identifica-
tion of gaps and problems with care delivery, (b) designation of
interventions to improve and solve them, and (c) prospective
assessment of the implementation of designed interventions to
make sure that the tasks have been well carried out. Quality
assurance relates to all diagnostic and therapeutic procedures
across the whole continuum of management, namely rapid and
easy access to early diagnosis using appropriate diagnostic meth-
ods (i.e. dermatoscopy, digital dermatoscopy), standardized
biopsy procedures, standardized complete histopathology
reports, appropriate risk classification and staging, appropriate
surgery and medical management and follow-up according to
clinical practice guidelines.
An example of implementing SOPs in daily care of patients
with skin cancer is the accurate documentation of cutaneous
tumours and informed selection on the methods of diagnosis
and treatment. If a skin cancer is suspected, clinical characteris-
tics such as the lesion’s location and diameter should be
recorded and macroscopic and dermatoscopic photographic
images should be captured and stored in the patient’s medical
file. All these data should be available prior to surgery in order
to optimize the histopathological evaluation and quality of diag-
nosis. Τhe standard therapy for skin cancer is surgical excision
followed by histopathological examination.36,37 A partial biopsy
(incisional, punch or shave) can be an alternative option to the
standard excisional biopsy in large tumours, tumours located on
sensitive areas (e.g. face and genitalia), and recurrent or diffi-
cult-to treat tumours, in order to confirm the diagnosis and plan
a subsequent complete excision or medical treatment. Destruc-
tive (blind) procedures such as curettage, cryotherapy and laser
ablation, as well as non-surgical treatments including photody-
namic therapy and topical therapies, either alone or combined,
do not allow for histopathological diagnosis and assessment of
the entire tumour.36,37
There is evidence that the quality of care for skin cancer, par-
ticularly for NMSC, differs between primary care and dermatol-
ogy. In a systematic review done in the UK, excisions led by
dermatologists had the highest overall and disease-free survival
rates compared to general practitioners (GPs), whereas plastic
surgeons were most likely to excise complex lesions on difficult-
to-treat areas.38 In a large cross-sectional study in the Nether-
lands, BCCs were more often completely excised by dermatolo-
gists than by GPs and plastic surgeons due to the dermatologist’s
extensive training and high experience in BCC care.39 These
findings support the need for education and collaboration with
other specialties, as discussed hereafter.
A significant challenge to ensuring quality care for all skin can-
cer patients is the high disparities across the whole continuum of
cancer care, manifest in Europe along a North-South, West-East
gradient. Eastern European countries have reported poorer out-
comes of skin cancer,40,41 face more frequent late diagnosis,42,43
have less capacity for skin cancer registration and reporting,44 lag
behind in preventive efforts,45 are less well equipped for early
diagnosis46 and struggle with important shortcomings in access to
innovative life-saving therapies for skin cancers.47 Therefore, the
European guidelines, recommendation of best practice, certifica-
tion and other initiatives of quality assurance must be accompa-
nied by a constant preoccupation of supporting and monitoring
their implementation in countries facing challenges, so that the
minimal requirements for quality cancer care in skin cancer 48 are
met across the entire continent, without painful gaps.
Professional Societies and National Medical Societies produce
and frequently update guidelines in order to introduce evidence-
or expert-based recommendations for high-quality, standardized
care. Over the last decade, the EDF, EADO and EORTC have
been very successful in developing European guidelines covering
all major skin cancers. The first European guideline on mela-
noma appeared in 2010 and was updated in 2013, 2016 and
2019.37,49 In 2019, guidelines for basal cell carcinoma were pub-
lished and those for squamous cell carcinoma were updated.36,50
Furthermore, European guidelines for dermatofibrosarcoma
protuberans, Merkel cell carcinoma and Kaposi’s sarcoma were
reported.51–53 These guidelines, which are led by dermatologists,
are continuously updated in cooperation with the above-men-
tioned European medical societies.
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Establishment of multidisciplinary skin tumour
centres
Treating patients with cancer in dedicated wards began at the
end of the 18th century in the United States and mid-19th cen-
tury in Europe, but the formalization and accreditation of com-
prehensive cancer centres at the national and even European
level emerged only recently, in the early 2000s.54,55 At present,
high-quality cancer care should be patient-centred and for skin
cancers, such care requires clear pathways with reasonable and
traceable timelines, in either direction, between GPs, dermatolo-
gists and multidisciplinary skin tumour centres (MSTCs). The
patients’ journey should be adapted to the patients’ needs which
may vary from one country or region to another. A MSTC has
five major interconnected missions: (a) clinical management of
patients, (b) research, (c) education and training, (d) quality
assurance capacities and (e) participation in national and Euro-
pean networks. Providing high quality of care relies on decisions
taken within multidisciplinary tumour boards by a multidisci-
plinary team (MDT) where dermatologists/dermato-oncologists
are key players in the management of skin cancers.
A MDT meets at least every week, discusses the most complex
cases and decides the best possible management or treatment for
each individual patient. The assurance of quality of care is closely
related to qualification and experience of each member of the
group. Therefore, the core of the MDT is represented by board
certified dermatologists with a special interest or certification in
oncology (dermato-oncologists) with good experience in the
diagnosis and management of skin cancer including the use of
targeted therapies, immunotherapies and chemotherapies, or
medical oncologists with a specific and dedicated interest in skin
cancers. Around this core group, MDT includes other profession-
als with good knowledge and experience on skin cancers: sur-
geons (dermatosurgeons, plastic surgeons, surgical oncologists),
pathologists, molecular pathologists, radiologist(s), including
interventional radiologists, nuclear medicine physicians and
radiotherapists. The expertise of various other disciplines is fre-
quently needed: geriatric oncologists for patients over 75 years
old, pharmacists, psycho-oncologists, palliative care, specialized/
advanced practice nurses and study coordinators.
Multidisciplinary skin tumour centre gain expertise from
management of a sufficient number of patients per year, and
some countries have proposed thresholds (e.g. 20 advanced mel-
anomas per year in the Netherlands, 40 in Germany).48 This is
even more important for rare skin cancers, such as Merkel cell
carcinoma, sarcomas and adnexal tumours, which should be
managed in the context of dedicated networks. Decisions for
MSTCs should be based on European and/or national guidelines
published in peer-reviewed scientific journals, shared with the
team and proposed transparently to patients who need to be
involved in the decisions. In addition, access to innovative thera-
pies through clinical trials should be available either in the centre
or by referring patients to other centres. Contribution from
MSTCs to national and European registries and biobanks should
be also encouraged. Clinical, process and patient-reported out-
comes, including severe adverse events, overall survival rates and
adherence to guidelines, should be measured, regularly audited
(internal and external audits) and made available to patients.
Finally, education programmes for professionals and patients
should be offered not only at MSTCs but also in the context of
regional, national and international networks.48,56
Development of integrative dermato-oncology
The complexity of skin cancer care is exploding, with rapidly
evolving new options in adjuvant, loco-regional and systemic
treatment, along with a changing paradigm for surgical
approaches. This is paralleled not only by new concepts of
molecular classification and prognostic markers, an increasing
demand to manage challenging new adverse effects, but also a
set of new survivorship issues in the context of unprecedented
survival rates through innovative therapies. In this setting, the
optimal skin cancer care is the patient-centred one. As discussed
above, this implies a multidisciplinary discussion and decision
on each individual case, but at the same time also requires an
integrated implementation of the decided care plan.48
This integration needs to be achieved at multiple levels: joint
care under the supervision of one case-managing specialist, inte-
grated care in terms of facilities and infrastructure used, and an
integrated reimbursement plan for the whole care continuum.
The bundling of diagnosis, surgical therapy and systemic ther-
apy in one team is preferred by patients, increases the compe-
tence for an individualized therapy and can facilitate treatment
adherence. There are currently three models of care of dermato-
oncology in Europe: (a) integrated care under the charge of der-
matology specialists with dermato-oncological competence
(German-speaking countries, France, some centres in Czech
Republic, Serbia and other countries), (b) diagnosis and surgery
together, with systemic therapy by oncologists and/or dermatol-
ogists (Mediterranean countries), and (c) diagnosis by dermatol-
ogists, surgery by surgeons/plastic surgeons with systemic
therapy by medical oncologists (United Kingdom, Scandinavia
and the majority of Eastern Europe).54
The last model increasingly occurs under pressure in the cur-
rent complex healthcare context. It often leads to fragmented
care, with lack of communication and information sharing
between specialties, use of different specialty-specific sets of
national guidelines and therapy protocols, lack of comparability
and agreement on results of diagnostic tests, and foremost the
need for typically fragile patients to be physically moved between
offices, wards, hospitals, and even cities, as not all necessary
facilities and administrative checkpoints are in one place. The
development of adjuvant and neoadjuvant therapy also interferes
with the efficacy of this model. The different recommendations
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020, 34, 2183–2197
Dermatologists’ role in Dermato-oncology 2189
received within a few weeks by multiple specialists may be con-
fusing for the patient.
Integrative dermato-oncology is well supported by the current
successful model of German-speaking countries and France.57 It
is further corroborated by the fact that dermatologists are the
most informed about the natural course and particularities of
skin tumours, they are already experienced in the diagnosis, local
surgical or non-surgical treatment, and follow-up of skin
tumours, as well as the management of skin toxicities of onco-
logical therapies. Thus, dermatologists are already an indispens-
able part of the skin cancer patients’ management along all steps
of their care continuum. Moreover, due to their current curric-
ula and training as reflected in the standard of the Union Euro-
peenne des Medecins Specialistes (UEMS), dermatologists have
solid internal medicine training, are trained to manage autoim-
mune diseases and severe reactions, and currently manage sys-
temic immune-biological drugs (like in psoriasis, atopic
dermatitis, autoimmune diseases). In addition, the EADO has
set up a programme to help train specialists in dermato-oncol-
ogy. This includes the annual conference of the European School
of Dermato-Oncology in Berlin, a fellowship programme with
internships in interdisciplinary skin tumour centres and both
examinations and certificates in systemic therapy of tumours.
Whenever possible, the dermatologist with competence in
dermato-oncology should be in charge of the integrated care of
skin cancer patients on the whole continuum, not only preven-
tion and diagnosis but also systemic treatment, including clinical
trials and follow-up, under consultation with the multidisci-
plinary tumour board and in close cooperation with other rele-
vant specialties. The legislative, administrative and
reimbursement framework should be adjusted accordingly. This
should not be interpreted as competition with other specialties
but as collaboration and an extension of high-quality services
offered to patients to ensure integrated care and avoid the obsta-
cles of shortages of personnel and capacity. This format of care
can lead to better patient outcomes, since a higher number of
qualified medical professionals are involved in patient care. For
example, in countries where both dermato-oncologists and med-
ical oncologists are prescribing systemic therapy, the mortality
to incidence ratio as a surrogate marker for fatality rate is lower.
Conversely, in countries where legislative restrictions to pre-
scribe systemic therapy and reimbursement restrictions based on
medical specialty exist, the mortality to incidence ratio is
higher.54
For the development of integrative dermato-oncology, the
necessary steps are as follows:
1 Improve and optimize education and training: It is necessary
to establish standardized advanced dermato-oncology train-
ing as a supra-specialization in medical tumour therapy of
skin cancers as a choice for dermatologists. Models of 1-year
supra-specialization exist in Germany, Austria, France,
Switzerland, Serbia, Croatia and elsewhere. This model of
supra-specialization (or supra-competence) merits encour-
agement in other countries. A major step was the introduc-
tion of the EADO-UEMS joint certification in medical
tumour therapy in dermato-oncology. Further efforts are
needed at the EADO-UEMS level to standardize the recom-
mended curricula for this. It is also important to reinforce
the existing basic training in the fundamentals of skin cancer
(i.e. early diagnosis, prevention, follow-up and recognition of
skin toxicities) and management for all general dermatolo-
gists according to the current UEMS curricula recommenda-
tion, and to ensure that these criteria of education quality are
uniformly implemented across Europe.58 Courses and e-
learning modules, developed in cooperation between EADV
and EADO, have been running at the European level or are
currently being developed, and would be a key contribution
to ensuring uniform high-quality training and supporting the
appropriate training of all dermatologists.
2 Enhance the participation of dermatologists in multidisciplinary
tumour boards: This is predicated on the fundamental con-
cept that the optimal personalized management plan for each
patient is achieved only by multidisciplinary discussion and
consensus. This reinforcement should not only be through
educating dermatologists, but also through supporting
administrative and regulatory change in order to facilitate the
creation and functioning of MDTs on a wide scale. In some
countries, it would be necessary to reformulate the legislative
framework to support the functioning of MDTs and the abil-
ity of appropriately competent dermatologists to manage the
integrated care of skin cancer patients. Also, in some coun-
tries it would be necessary to reformulate the reimbursement
regulation to allow the dermatologist to be in charge of inte-
grated care, under consultation with the MDT (Table 3).
3 Authorize dermatologists to participate in clinical trials with
direct investigator responsibilities: This will allow direct access
to innovative drugs and better enable dermatologists to attain
early practical experience with these medications, and in the
management of their side-effects. Recent surveys conducted
by the EADO group point to a high need for dermatologists
Table 3 Summary of steps for the successful development of
integrative dermato-oncology
• Establish standardized advanced dermato-oncology training as a supra-
specialization in medical tumour therapy of skin cancers as a choice for
dermatologists.
• Reinforce the existing training in skin cancer (basic level) for all general
dermatologists, according to the current UEMS curricula recommenda-
tions. Ensure that these quality criteria are uniformly implemented across
Europe.
• Enhance the participation of dermatologists in multidisciplinary tumour
boards. Reformulate the legislative framework to support the functioning
of MDTs and the ability of appropriately competent dermatologists to coor-
dinate the integrated care of skin cancer patients.
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and dermato-oncologists to develop good-quality MSTCs
and improve access to innovative therapies and trials in
countries with low GNI per capita.47,59
Optimizing tumour follow-up
Dermatologists play a central role in the follow-up of patients
with skin cancers, and their role definitely extends beyond skin
examination (Table 4). The follow-up of skin cancer patients is
of great importance as its objectives are manifold: to detect the
primary tumour’s recurrences or relapses as early as possible
(which immediately influences the treatment decision), to detect
new secondary skin cancers early60–62 and other possibly subse-
quent malignancies,63,64 to monitor and manage the side-effects
of antitumoural therapies, and also to provide patients with edu-
cation, counselling and support for prevention actions, both for
themselves and their families. According to the recent versions
of European and other international guidelines for skin cancer
from EADO, EDF, EORTC and ESMO as well as the NCCN mel-
anoma guidelines,37,49,65,66 the frequency and extent of follow-
up visits and tests depend upon the risk of relapse and risk fac-
tors for subsequent skin cancers (e.g. multiple NMSCs,
immunosuppression, multiple nevi, family and personal history
of melanoma, mutation status in high-penetrance melanoma
genes, and history of sunburns).
In general, the following strategies are recommended:
1 Careful evaluation of reported symptoms.
2 Clinical total body skin examination, complemented by the
dermatoscopic evaluation of skin lesions and digital follow-
up in patients with multiple nevi/atypical mole syndrome.
Dermatoscopy, which is used by the vast majority of derma-
tologists, improves diagnostic accuracy, avoids unnecessary
excisions and allows for early diagnosis of skin cancers.67,68
3 Physical examination of the scar area and regional lymph
nodes.
4 Blood testing and imaging tests.
The first three strategies are managed by dermatologists and
are mandatory for the follow-up of all patients, while blood and
imaging tests have schedules and indications that differ accord-
ing to tumour stage and additional risk factors. In patients with
invasive melanoma, a more intensive follow-up is recommended
in the first 5 years following surgery, since most recurrences
occur during this time period. However, metastasis can also
occur 10 years and more after a melanoma diagnosis (especially
in thinner tumours), which indicates the relevance of patient
education and access to medical evaluation across a lifetime.
Clinicians can recommend that their patients access numerous
patient education leaflets produced online by EADV on mela-
noma and NMSCs, as well as other skin conditions.69 In the
EADO and NCCN guidelines, radiology tests with ultrasound,
CT, MRI and/or PET/CT are considered in stage IIB, IIC, III and
IV to detect asymptomatic metastasis and in any case with asso-
ciated symptoms.37,65,70,71
In patients with epithelial skin cancers, standard follow-up
facilitates early detection of secondary tumours, local recur-
rences and metastases.36,50,72 No impact on survival has been
shown so far, but this is reasonable since no randomized studies
comparing intensive and non-intensive follow-up schedules have
been conducted. In addition to improving early diagnosis of sec-
ondary and/or recurring skin cancers, follow-up examinations
performed by dermatologists allow them to implement the
appropriate treatment, which usually is surgical. The latter seems
to be beneficial for patients, since several studies highlight that
surgical treatment of skin cancers by dermatologists decreases
the risk of incomplete excisions and reduces the costs of such
interventions. 39,73–77
Primary cutaneous lymphoma and rare malignant
skin tumours
Besides melanoma and epithelial skin cancers, rare malignant
skin tumours have recently been in the spotlight due to their
increasing incidence, their distinct pathogenetic and molecular
mechanisms, and their improved outcomes due to new treat-
ments. Although for some of these tumours, such as primary
cutaneous lymphomas (PCL), Merkel cell carcinoma or Kaposi’s
sarcoma, specific guidelines do exist, for others such as adnexal
tumours, there is still a need for consensus or evidence-based
management.51–53
Primary cutaneous lymphomas encompass a heterogeneous
spectrum of lymphoproliferative diseases with different clinical
presentations, histological, immunological and molecular fea-
tures, among which mycosis fungoides (MF) is the most fre-
quent. The prognosis ranges from indolent such as
lymphomatoid papulosis, early-stage MF, primary marginal and
follicle centre B-cell lymphoma, to aggressive forms such as
Sezary syndrome, advanced-stage MF, peripheral T-cell lym-
phomas and diffuse large B-cell lymphoma, leg type.78 The
prevalence of PCL is increasing due to better diagnostic tools;
Table 4 Consensus-based European international guidelines, rec-
ommendations and general goals of follow-up of patients with skin
cancer
• Identify early detection of recurrent disease (local, distant) at the earliest
stage.
• Recognize and treat complications of surgical interventions (e.g. pain, lym-
phoedema, infections and paraesthesia) and side-effects related to sys-
temic treatment (adjuvant, neoadjuvant or locally advanced/metastatic
disease therapy).
• Diagnose subsequent secondary skin cancers and possibly other related
cancers.
• Provide education of the patient and his/her/their family on self-skin exami-
nation and symptoms related to disease and on personal and family risk
factors.
• Offer psychosocial support and information about the disease, diagnosis,
therapy and prognosis and provide the patient and first-degree relatives
with education on prevention and access to consultation in case of clinical
symptoms.
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however, overall survival has not changed in recent years.79 Pri-
mary prevention is not possible as there are no known predis-
posing environmental factors for disease prevention.
Nevertheless, secondary prevention is very important, leading to
detection and diagnosis at an early stage, which might lead to
more effective treatment or potentially improve survival. The
International prospective database Proclipi80 has shown that
there is a median delay of 3 years between first symptom devel-
opment and initial diagnosis. This could be attributed to lack of
a singular diagnostic test and available reliable biomarkers, mak-
ing early diagnosis difficult and based on clinico-pathological
correlations,81 integrated by molecular studies (clonality) and
flow cytometry (for differential diagnosis of Sezary syndrome
with other erythrodermic diseases as well as proper staging of
patients).82 Therefore, it is very important to address all cuta-
neous lymphoma suspicions to specialist reference teams to
allow for proper clinico-pathological diagnosis and to define the
best management. This can be done through specialized lym-
phoma centres with MDTs (dermatologists, haematologists,
oncologists and pathologists) with appropriate diagnostic facilities
such as histopathology and immunology for flow cytometry, as
well as the best treatment approach at the right time like total-
skin electron beam (TSEB) radiotherapy, extracorporeal photo-
pheresis and allogeneic transplantation. New techniques are
becoming available and allow a small amount of genetic material
to detect malignant DNA such as T-cell receptor rearrangement
with high-throughput sequencing, and next-generation sequenc-
ing (NGS) vs. Sanger sequencing. Thus, dermatologists play a
major role in the diagnosis, treatment and follow-up of these
patients. However, this is framed only in the context of a multi-
disciplinary approach where, according to the diagnosis and clini-
cal stage, other colleagues from different specialities are mainly
involved (the pathologist and molecular biologist for diagnosis,
and radiotherapist, oncologist or haematologist for treatment).
Indeed, treatment options range widely from skin-directed-thera-
pies (e.g. topical steroids, phototherapy, radiotherapy either as
localized or TSEB radiotherapy), systemic treatments (e.g. reti-
noids, low-dose methotrexate, interferons or photopheresis),
immunotherapy (e.g. rituximab, brentuximab or alemtuzumab)
and chemotherapy (e.g. gemcitabine, doxorubicin or CHOP) to
allogeneic bone marrow transplantation.83–85
The combination of accurate detection of the malignant clone
and mutations could lead to the development of ‘personalized
therapy’ in a scenario of precision medicine according to patient
molecular phenotype and mutations, as chemotherapy is
weighted by severe side-effects and short response duration.
Innovative methods in dermato-oncology
Teledermatology
The lack of dermatologists in several European countries and
population ageing along with increasing skin cancer incidence
has challenged healthcare organizations. This has led to an
increase in use of e-Health and teledermatology over the last
10 years. Sensitivity has been found to be comparable between
teledermoscopy and face-to-face evaluations, although specificity
was higher in face-to-face evaluations.86 Many studies have
shown that for SCS, up to 50% of teledermatology referrals can
be downgraded to routine appointments or patients discharged
with reassurance.87–89 Up to 40% of teledermatology referrals
for skin lesions are sent straight to biopsy lists without necessi-
tating face-to-face appointments beforehand, so waiting times
are reduced.87–89 Furthermore, for large lesions, patients can be
referred directly to dermatosurgeons or plastic surgeons. Most
of these teledermatology clinics involve nurses taking a history
and pictures, including dermoscopic images, with referrals chan-
nelled to dermatologists with a very fast turnaround.
However, since the COVID-19 pandemic, these nurse-led
clinics have not been running, so dermatologists have adapted
their practice. Patients have had the opportunity to use similar
or adapted software where they can take photographs at home
and upload them online. Video consultations are also part of
several new types of teledermatology software, so if the derma-
tologist would like to take an in-depth history, they can speak to
the patient remotely. Although dermatologists would obviously
prefer to have dermoscopy pictures as this definitely improves
accuracy, the use of teledermatology with photographs taken by
patients and relatives for the triage of skin lesions has been
invaluable during the COVID-19 pandemic. Dermatologists
have been able to resolve more than 80% of teledermatology
referrals and triage the patient to the appropriate pathway or
advise them remotely without the need to have face-to-face vis-
its. Inpatient referrals can also be dealt in the same way, with the
ward nurses taking pictures and sending the referral online to
the dermatology team. The teaching of trainees also benefits
from these remote clinics, as all images and outcomes can be
used for training purposes. Teledermatology software also allows
for instant auditing of practices with assessment of diagnoses,
turnaround times and outcomes. Therefore, there is a need to
make sure that changes in practice imposed by the COVID pan-
demic lead to dermatology being delivered in a different way in
the future, in order to avoid going back to face-to-face dermatol-
ogy only for SCS whenever it is not essential.90,91
In recent years, a number of mobile apps in skin cancer have
been launched with different categories of applications including
(most commonly) teledermatology, followed by self-surveil-
lance/diagnosis, disease guide and general dermatology. Teleder-
matology apps have experienced notable growth and had tripled
in number from 2014 to 2017.92
Mobile apps and other electronic resources have the potential
to improve access and outcomes for skin cancer patients, but
these resources must be utilized with appropriate protocols and
guidelines and with caution, as patients need to be educated
about their benefits and limitations. Current algorithm-based
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smartphone apps to assess images of skin tumours suspicious for
skin cancer cannot be relied upon to detect malignant tumours
according to the results of published studies.93,94 Further testing
must be conducted in real-life situations to evaluate the reliabil-
ity of these healthcare apps for skin cancer used by patients.
Genomic medicine
Novel treatments and increasingly available and affordable NGS
techniques have created an opportunity for delivering genomi-
cally informed personalized cancer therapy and prognostic esti-
mation. Implementing the use of these technologies in the
clinical setting requires a clinician’s knowledge on interpreting
the genetic profile of the patient, including molecular characteri-
zation of the tumour and germline DNA examination.
For the practising dermatologist and dermato-oncologist, the
field of cancer genomics may appear daunting; however, the aim
is not to identify all genetic alterations in the tumour or germ-
line but instead to know how to best use emerging genetic
knowledge for prognostic and therapeutic optimization. Genet-
ics in oncology will become more important as genetic panels
have been developed for many cancers and are now tested in tri-
als including larger cohorts of patients to better predict progno-
sis and responses to treatment. At this stage, whole NGS of
germline and somatic DNA is not used in clinical practice with
the exception of very rare tumours or syndromes. However,
research in the whole genomic era is moving fast with clear
potentials in the areas of diagnosis, prognosis and treatment.95
Five to 10% of melanoma patients present with a significant
family history of cancer, and this is often poorly documented.
Although formal consultation by cancer geneticists is required,
dermatologists should assist in the counselling and follow-up of
these families. Families with multiple melanomas should undergo
genetic testing using a germline familial melanoma panel
(CDKN2A, CDK4, MITF, BAP1, POT1 and other telomere genes
if possible)96 as well as tests for alterations in other cancer genes
(BRCA1, BRCA2, ATM, etc.). It is important to establish clear
indications for genetic testing in skin cancer and develop expertise
in the interpretation of these panels as many variants may be, so
far, classified as being of unknown clinical significance. It is clear,
however, that as many more families are being tested, the signifi-
cance of all reported variants will become clearer.
The identification of somatic mutations in melanoma revo-
lutionized its treatment.97,98 Approximately 50% of tumours
harbour BRAF mutations, and this test is now part of stan-
dard practice in all melanoma clinics dealing with stage III
and IV disease. Mutations that activate BRAF and NRAS, two
critical nodes of the MAPK signalling cascade, cumulatively
occur in 75% of melanomas;99 thus, the need to test for these
mutations should be known by all dermatologists and physi-
cians involved in skin cancer treatment. The presence of
BRAF mutations opens the therapeutic landscape to targeted
gene treatments.
There are not, at this point, any specific somatic mutations
that can reliably predict response to immunotherapy. However,
there are other tumour-related factors that might affect
response, such as lymphocytic infiltrate, PD-L1 positivity, high
interferon gamma signature and high tumour mutational bur-
den.100 It is likely that, with advances in genomic research, better
predictors of response to both targeted and immune-mediated
treatments will become available.
Dermatologist’s role in patient advocacy and
public health campaigns in skin cancer in Europe
Since the majority of skin cancers are attributable to UVR and,
thus, potentially preventable,11 a major role of dermatologists
focuses on raising public awareness and leading public health
campaigns. Although the real impact of sun protection and early
detection on the long-term mortality of skin cancers is yet unde-
termined, Australian initiatives and successes are encouraging
for European stakeholders to promote similar measures.101,102 It
is, therefore, crucial to strengthen bonds with key policy actors
at national and international levels to bring this important
health issue to the forefront of the health agenda.103 Already
since 2007, EADV together with Euromelanoma, the European
Cancer Leagues and Members against Cancer started a dialogue
and held press conferences in the EU Parliament, supported by
the World Health Organization. Their objectives were to pro-
mote the importance of early diagnosis of skin cancer, discuss
ways to improve skin cancer registration, emphasize the danger
of using sunbeds and create awareness and protect the vulnera-
ble group of outdoor workers exposed to occupational UVR. In
outdoor workers, UVR is an inevitable carcinogen; therefore, the
prevention and management of UVR-related skin cancers in
these at-risk populations represent a collective challenge for der-
matologists and healthcare policymakers likewise.104 Since then,
such activities have been held regularly in the EU parliament
and have resulted in numerous questions addressed by Parlia-
ment members to the Commission to attract attention and
obtain answers on these key issues. Furthermore, charts, call to
actions and ‘white books’ have been drafted for these important
issues, co-signed under EADV initiatives bringing together all
important associations and stakeholders.
Meanwhile, with the Euromelanoma campaign that started in
Belgium in 1999 and is now active in 33 countries, European
dermatologists have succeeded in reaching the public, creating
awareness of skin cancer and the importance of early detection
by offering free annual skin cancer checks.26 The high acceptance
of this initiative shows the pivotal interest of the public in this
issue at all ages. While skin cancer is the most common type of
cancer in adults, it is considered rare in children. However, chil-
dren are the most susceptible to UV damage and are a very
important group to reach to promote primary prevention mes-
sages in order to reach their parents and avoid early-in-life dam-
age exposure with life-long increase of oncogenic risk. As a
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result, dermatologists in different European countries have led
campaigns in schools to educate as early as possible on safe
behaviour in the sun.105,106
Some of the most common situations that need careful input
from dermatologists are solid organ or hematopoietic stem cell
transplantation, cancer and cancer treatments, genodermatoses
and hereditary cancer syndromes, patients with sensitive skin to
sun damage, family history of skin cancer (especially mela-
noma), medications that suppress or modify the immune sys-
tem, medications that induce photosensitivity and history of
extensive sun exposure or use of tanning beds/indoor tan-
ning.101,102
Finally, patient knowledge and fears about skin cancers as
well as the burden associated with these lesions have not been
clearly established. Dermatologists are among the most con-
sulted medical specialists in Europe.101,103,107 They are per-
ceived by the general public as both fundamental caregivers
for mole checking/melanoma screening and nevi removal, but
awareness of their specific expertise in the diagnosis and treat-
ment of all skin cancers is not optimal.108–110 Furthermore, in
many countries, GPs, or primary care physicians/providers
(PCPs) are usually the first healthcare providers to be con-
sulted for skin problems. Better training of GPs/PCPs in the
detection of skin cancers in conjunction with better coordina-
tion of the patient care pathway from the GP/PCP towards
the dermatologist is mandatory. In addition, heterogeneity in
patient care pathways and healthcare systems across Europe
must be articulated with a general public understanding that
dermatologists are the specialists to be referred to when skin
cancers are detected by other clinicians.
The EADV is currently launching a pan-European survey to
better identify all potential barriers to overcome in order to
reduce the delay between detection of a tumour and its manage-
ment, in order to optimize care and devise efficient educational
strategies that will help lead patients with skin cancer to the
appropriately skilled specialist (i.e. the dermatologist).
Take steps for broad access to novel treatments (T) across Europe and
the EU and ensuring access to optimal cancer care for all patients with
melanoma and skin cancer
Improve registration (R) of melanoma and NMSC cases in order to
improve the epidemiological surveillance of the disease and inform
public health policies
Enhance research (R) on skin cancer epidemiology, prevention, and
treatment
Employ legislative and other preventive measures to reduce risk of 
overexposure of children, adolescents and adults to ultraviolet (U) 
radiation (natural and artificial)
Implement legislative measures to ensure improved sun protection (S) and
effective treatments for outdoor workers
Formulate a recommendation for screening (S) strategies in the general
population and in high-risk groups (older individuals, immunosuppressed
individuals, organ transplant recipients and patients with hereditary syndromes)
Establish an integrated patient-centred multidisciplinary approach for
patients/tumour boards (T) 
Figure 3 Addressing public health priorities in dermato-oncology (T.R.U.S.T.). HCPs: healthcare providers; NMSCs: non-melanoma skin
cancers.
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Conclusions
The field of dermato-oncology is wide and evolving. As new
insights emerge on the genetic and molecular mechanisms of
cutaneous oncogenesis, transformative technologies are being
incorporated into the diagnostic field, and novel treatments are
being implemented in the management of advanced cutaneous
tumours. These impressive changes have changed dermato-on-
cology dramatically from a narrow field with limited resources,
to a rapidly expanding discipline with improved patient out-
comes and a broader care perspective. This tremendous progress
opens up new priorities and needs on a public health scale which
are summarized in Fig. 3 (acronym ‘TRUST’). Dermatology–
Venereology has played a major part in these advances, ranging
from prevention to multidisciplinary care, and from early diag-
nosis to more precise disease staging and structured comprehen-
sive care. There is currently a need to broadly establish a
dermato-oncology training curriculum and clinical care pro-
grammes which uniformly meet a high level of quality across
Europe, in order to ensure that dermatologists continue to play
a leading role in the evolving multidisciplinary patient-centred
approach of patients with skin cancer.
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